ZA200005141B - Dosing regimens for lasofoxifene. - Google Patents

Dosing regimens for lasofoxifene.

Info

Publication number
ZA200005141B
ZA200005141B ZA200005141A ZA200005141A ZA200005141B ZA 200005141 B ZA200005141 B ZA 200005141B ZA 200005141 A ZA200005141 A ZA 200005141A ZA 200005141 A ZA200005141 A ZA 200005141A ZA 200005141 B ZA200005141 B ZA 200005141B
Authority
ZA
South Africa
Prior art keywords
lasofoxifene
dosing regimens
effect
potency
achieves
Prior art date
Application number
ZA200005141A
Other languages
English (en)
Inventor
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200005141B publication Critical patent/ZA200005141B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
ZA200005141A 1999-09-29 2000-09-26 Dosing regimens for lasofoxifene. ZA200005141B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15665299P 1999-09-29 1999-09-29

Publications (1)

Publication Number Publication Date
ZA200005141B true ZA200005141B (en) 2002-03-26

Family

ID=22560457

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200005141A ZA200005141B (en) 1999-09-29 2000-09-26 Dosing regimens for lasofoxifene.

Country Status (20)

Country Link
US (1) US6436977B1 (de)
EP (1) EP1092431B1 (de)
JP (1) JP2001097862A (de)
KR (1) KR100468246B1 (de)
AT (1) ATE339201T1 (de)
AU (1) AU781828B2 (de)
CA (1) CA2321369C (de)
CO (1) CO5200833A1 (de)
CY (1) CY1105235T1 (de)
DE (1) DE60030654T2 (de)
DK (1) DK1092431T3 (de)
ES (1) ES2269071T3 (de)
HU (1) HUP0003836A3 (de)
IL (1) IL138634A (de)
MY (1) MY121519A (de)
NZ (2) NZ516413A (de)
PE (1) PE20010680A1 (de)
PT (1) PT1092431E (de)
TW (1) TWI224001B (de)
ZA (1) ZA200005141B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
DE60219478T2 (de) 2001-07-06 2008-01-03 Endo Pharmaceuticals Inc. Orale gabe von 6-hydroxy-oxymorphon als analgetikum
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
EP2099443A4 (de) * 2006-11-10 2010-05-05 Syndax Pharmaceuticals Inc Kombination von er+-liganden und histondeacetylase-hemmern zur behandlung von krebs
WO2009015203A1 (en) * 2007-07-23 2009-01-29 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
WO2009015237A1 (en) * 2007-07-23 2009-01-29 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
WO2009058895A1 (en) * 2007-10-30 2009-05-07 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac and an mtor inhibitor
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
WO2009126662A1 (en) * 2008-04-08 2009-10-15 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac, an inhibitor of her-2, and a selective estrogen receptor modulator
WO2018071440A1 (en) 2016-10-11 2018-04-19 Duke University Treatment of breast cancer
CN117771239A (zh) 2018-04-10 2024-03-29 杜克大学 乳腺癌的拉索昔芬治疗

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296486A (en) 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
US5366965A (en) * 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
EP1004306A3 (de) 1998-08-06 2000-06-07 Pfizer Products Inc. Estrogen Agonisten/Antagonisten
EP1086692A3 (de) 1999-07-28 2003-07-09 Pfizer Products Inc. Oestrogen Agonisten und Antagonisten für mehrere Indikationen

Also Published As

Publication number Publication date
CA2321369A1 (en) 2001-03-29
HUP0003836A3 (en) 2002-09-30
EP1092431B1 (de) 2006-09-13
IL138634A0 (en) 2001-10-31
JP2001097862A (ja) 2001-04-10
HU0003836D0 (en) 2000-12-28
PE20010680A1 (es) 2001-06-29
HUP0003836A2 (hu) 2001-10-28
TWI224001B (en) 2004-11-21
ES2269071T3 (es) 2007-04-01
DE60030654T2 (de) 2007-04-05
KR20010061927A (ko) 2001-07-07
MY121519A (en) 2006-01-28
DE60030654D1 (de) 2006-10-26
PT1092431E (pt) 2006-12-29
IL138634A (en) 2006-08-01
EP1092431A3 (de) 2002-02-13
NZ516413A (en) 2004-12-24
AU5661800A (en) 2001-04-05
AU781828B2 (en) 2005-06-16
DK1092431T3 (da) 2006-12-18
CA2321369C (en) 2007-07-17
EP1092431A2 (de) 2001-04-18
KR100468246B1 (ko) 2005-01-27
US6436977B1 (en) 2002-08-20
CY1105235T1 (el) 2010-03-03
CO5200833A1 (es) 2002-09-27
ATE339201T1 (de) 2006-10-15
NZ507200A (en) 2004-12-24

Similar Documents

Publication Publication Date Title
HK1045650A1 (en) Pharmaceutical composition.
HUP0202489A3 (en) Compositions containing solubilized, acid-enhanced antiperspirant active
IL172695A0 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
TR200003787A3 (tr) Kararli yavas salimli oral dozaj bilesimi.
DK1157037T3 (da) GCSF-konjugater
HUP0203190A3 (en) Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
ZA200206905B (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same.
HK1034898A1 (en) Topical compositions for nsai drug delivery.
IL144026A0 (en) Phenylphenanthridine derivatives and pharmaceutical compostions containing the same
IL150225A0 (en) Lipopeptides, pharmaceutical compositions containing the same and methods for the production thereof
ATE312080T1 (de) 2-chinolonen enthaltende arzneimittel
HUP0102483A3 (en) Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol
MY134880A (en) Thiazolyl amide derivatives
ZA200203486B (en) Novel pharmaceutical compositions.
ZA200108248B (en) Antiperspirant compositions.
NZ507200A (en) Dosing regimens for lasofoxifene
SI1121127T1 (en) Oral pharmaceutical compositions containing buprenorphin
HUP0102671A3 (en) Immunosupressive pharmaceutical compositions containing 2',2'-difluoro-nucleoside analogues
ZA200109575B (en) Medicinal compositions containing anti-Fas antibody.
ZA200000857B (en) Pharmaceutical composition.
HK1049123A1 (zh) 單劑型後發泡性氧化染髮組合物
PL352104A1 (en) Oral composition containing perlite
HUP0202820A3 (en) Compositions containing solubilized antiperspirant active
RS47804A (en) 1,3-diarylprop-2-en-1-ones, compositions containing same and use thereof
ZA9810886B (en) Compositions for nasal administration.